{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:30:37Z","timestamp":1789475437493,"version":"build-2803163510"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The type III interferon family, known as interferon lambda (IFN-\u03bb), consists of four isoforms (IFN-\u03bb1, IFN-\u03bb2, IFN-\u03bb3, and IFN-\u03bb4) and plays essential roles in immune responses. It mediates anti-viral and anti-tumoral activities and is distinguished from type I and type II interferons (IFNs) by its interaction with a unique receptor complex involving IFN-\u03bbR1 and IL-10\u2009R\u03b2 predominantly expressed on epithelial cells and selected immune cell populations. This interaction results in activation of the JAK-STAT signaling pathway and transcription of interferon-stimulated genes (ISGs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>IFN-\u03bbs exert anti-viral activities, particularly at epithelial and barrier surfaces, and have emerged as therapeutic agents for chronic viral infections like hepatitis C virus and influenza, providing an alternative to traditional IFN therapies with a more favorable safety profile. Beyond these anti-viral properties, IFN-\u03bbs contribute to tumor control by enhancing immune surveillance and modulating the composition of the tumor microenvironment. However, accumulating evidence indicates that IFN-\u03bb cells may also exhibit pro-tumorigenic potential by promoting immune evasion and tumor progression in certain contexts. These opposing functions underscore the complexity of IFN-\u03bb biology and the need for further research to elucidate the mechanisms governing its actions, identify biomarkers that predict IFN response and to develop targeted strategies that maximize its therapeutic benefits, while minimizing adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By elucidating the complex interplay between IFN-\u03bb and the immune system, this review provides insights into its dual functions in immune-related diseases, its potential as a biomarker for disease monitoring and prediction of therapy response, and its potential for the development of targeted therapies in cancer treatment and viral infections. However, to improve the patients\u2019 outcomes in infectious diseases and cancer management, a comprehensive understanding of its context-specific effects is required to optimize its clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08209-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:57:40Z","timestamp":1778039860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential"],"prefix":"10.1186","volume":"24","author":[{"given":"Juliane","family":"Bl\u00fcmke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-4958","authenticated-orcid":false,"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"1","key":"8209_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/NI875","volume":"4","author":"V Kotenko S","year":"2003","unstructured":"Kotenko S V, Gallagher G, Baurin V V, Lewis-Antes A, Shen M, Shah NK, et al. IFN-\u03bbs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003, Jan, 1;4(1):69\u201377. https:\/\/doi.org\/10.1038\/NI875 PubMed PMID: 12483210.","journal-title":"Nat Immunol"},{"issue":"2","key":"8209_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164\u201371. https:\/\/doi.org\/10.1038\/ng.2521 PubMed PMID: 23291588.","journal-title":"Nat Genet"},{"issue":"1","key":"8209_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003, Dec, 2;4(1):63\u201368. https:\/\/doi.org\/10.1038\/ni873 PubMed PMID: 12469119.","journal-title":"Nat Immunol"},{"issue":"31","key":"8209_CR4","doi-asserted-by":"publisher","first-page":"20869","DOI":"10.1074\/jbc.M109.002923","volume":"284","author":"HH Gad","year":"2009","unstructured":"Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-\u03bb is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem. 2009, Jul, 31;284(31):20869\u201375. https:\/\/doi.org\/10.1074\/jbc.M109.002923 PubMed PMID: 19457860.","journal-title":"J Biol Chem"},{"issue":"3","key":"8209_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/J.IMMUNI.2017.02.017","volume":"46","author":"JL Mendoza","year":"2017","unstructured":"Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, et al. The IFN-\u03bb-IFN-\u03bbR1-IL-10R\u03b2 complex reveals structural features underlying type III IFN functional plasticity. Immunity. 2017, Mar, 21;46(3):379. https:\/\/doi.org\/10.1016\/J.IMMUNI.2017.02.017 PubMed PMID: 28329704.","journal-title":"Immunity"},{"key":"8209_CR6","doi-asserted-by":"publisher","unstructured":"Grubbe WS, Zhang B, Kauffman A, Byl\u00e9hn F, Pado\u0142 K, Jung HG, et al. Structural studies of the IFN\u03bb4 receptor complex using cryoEM enabled by protein engineering. Nat Commun. 16(1):1\u201312. https:\/\/doi.org\/10.1038\/s41467-025-56119-y. 2025 Jan 18 PubMed PMID: 39827213.","DOI":"10.1038\/s41467-025-56119-y"},{"key":"8209_CR7","doi-asserted-by":"publisher","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Sig Transduct Target Ther. 6(1):1\u201333. https:\/\/doi.org\/10.1038\/s41392-021-00791-1. 2021 Nov 26 PubMed PMID: 34824210.","DOI":"10.1038\/s41392-021-00791-1"},{"issue":"8","key":"8209_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ni.3212","volume":"16","author":"A Wack","year":"2015","unstructured":"Wack A, Terczy\u0144ska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015, Jul, 21;16(8):802\u201309. https:\/\/doi.org\/10.1038\/ni.3212. 3212, PubMed PMID: 26194286.","journal-title":"Nat Immunol"},{"key":"8209_CR9","doi-asserted-by":"publisher","unstructured":"Stanifer ML, Guo C, Doldan P, Boulant S. Importance of type I and III interferons at respiratory and intestinal barrier surfaces. Front Immunol. 2020, Dec;11:608645. https:\/\/doi.org\/10.3389\/fimmu.2020.608645 PubMed PMID: 33362795.","DOI":"10.3389\/fimmu.2020.608645"},{"issue":"12","key":"8209_CR10","doi-asserted-by":"publisher","first-page":"731807","DOI":"10.3389\/fimmu.2021.731807","volume":"12","author":"S Krammer","year":"2021","unstructured":"Krammer S, Sicorschi Gutu C, Grund JC, Chiriac MT, Zirlik S, Finotto S. Regulation and function of interferon-lambda (IFN\u03bb) and its receptor in asthma. Front Immunol. 2021, Nov;12(12):731807. https:\/\/doi.org\/10.3389\/fimmu.2021.731807 PubMed PMID: 34899691.","journal-title":"Front Immunol"},{"issue":"12","key":"8209_CR11","doi-asserted-by":"publisher","first-page":"998584","DOI":"10.3389\/fcimb.2022.998584","volume":"12","author":"MC Lee","year":"2022","unstructured":"Lee MC, Yu CP, Chen XH, Liu MT, Yang JR, Chen AY, et al. Influenza a virus NS1 protein represses antiviral immune response by hijacking NF-\u03baB to mediate transcription of type III IFN. Front Cell Infect Microbiol. 2022, Sep;12(12):998584. https:\/\/doi.org\/10.3389\/fcimb.2022.998584 PubMed PMID: 36189352.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"8209_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/infdis\/jix593","volume":"217","author":"BR Rosenberg","year":"2018","unstructured":"Rosenberg BR, Freije CA, Imanaka N, Chen ST, Eitson JL, Caron R, et al. Genetic variation at IFNL4 influences extrahepatic interferon-stimulated gene expression in chronic HCV patients. J Infect Dis. 2018, Jan, 30;217(4):650\u201355. https:\/\/doi.org\/10.1093\/infdis\/jix593 PubMed PMID: 29165633.","journal-title":"The J Infect Dis"},{"issue":"9","key":"8209_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/NRI1684","volume":"5","author":"T Decker","year":"2005","unstructured":"Decker T, M\u00fcller M, Stockinger S. The Yin and Yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005, Sep;5(9):675\u201387. https:\/\/doi.org\/10.1038\/NRI1684 PubMed PMID: 16110316.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8209_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/ANNUREV-IMMUNOL-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513\u201345. https:\/\/doi.org\/10.1146\/ANNUREV-IMMUNOL-032713-120231 PubMed PMID: 24555472.","journal-title":"Annu. Rev. Immunol"},{"issue":"2","key":"8209_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/J.JHEP.2012.01.029","volume":"57","author":"B Gao","year":"2012","unstructured":"Gao B, Wang H, Lafdil F, Feng D. STAT proteins \u2013 key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Educ Chang Hepatol. 2012, Aug;57(2):430. https:\/\/doi.org\/10.1016\/J.JHEP.2012.01.029 PubMed PMID: 22504331.","journal-title":"J Educ Chang Hepatol"},{"issue":"8","key":"8209_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/NI.2915","volume":"15","author":"C Odendall","year":"2014","unstructured":"Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat Immunol. 2014;15(8):717. https:\/\/doi.org\/10.1038\/NI.2915 PubMed PMID: 24952503.","journal-title":"Nat Immunol"},{"key":"8209_CR17","doi-asserted-by":"publisher","unstructured":"Wei H, Wang S, Chen Q, Chen Y, Chi X, Zhang L, et al. Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection. PLoS Pathog. 2014;10(1):e1003845. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1003845 PubMed PMID: 24391501.","DOI":"10.1371\/JOURNAL.PPAT.1003845"},{"issue":"1","key":"8209_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.IMMUNI.2015.07.001","volume":"43","author":"HM Lazear","year":"2015","unstructured":"Lazear HM, Nice TJ, Diamond MS. Interferon-\u03bb: immune functions at barrier surfaces and Beyond. Immunity. 2015, Jul, 21;43(1):15. https:\/\/doi.org\/10.1016\/J.IMMUNI.2015.07.001 PubMed PMID: 26200010.","journal-title":"Immunity"},{"issue":"14","key":"8209_CR19","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1128\/JVI.02438-06","volume":"81","author":"Z Zhou","year":"2007","unstructured":"Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-Like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007, Jul, 15;81(14):7749\u201358. https:\/\/doi.org\/10.1128\/JVI.02438-06 PubMed PMID: 17507495.","journal-title":"J Virol"},{"issue":"3","key":"8209_CR20","doi-asserted-by":"publisher","first-page":"115286","DOI":"10.1016\/J.CELREP.2025.115286","volume":"44","author":"M Nakajima-Koyama","year":"2025","unstructured":"Nakajima-Koyama M, Kabata M, Lee J, Sogabe Y, Sakurai S, Hirota A, et al. The balance between IFN-\u03b3 and ERK\/MAPK signaling activities ensures lifelong maintenance of intestinal stem cells. Cell Rep. 2025, Mar, 25;44(3):115286. https:\/\/doi.org\/10.1016\/J.CELREP.2025.115286 PubMed PMID: 39952238.","journal-title":"Cell Rep"},{"issue":"2","key":"8209_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4049\/JIMMUNOL.1102041","volume":"189","author":"T Matsuzawa","year":"2012","unstructured":"Matsuzawa T, Kim BH, Shenoy AR, Kamitani S, Miyake M, MacMicking JD. IFN-\u03b3 Elicits macrophage autophagy via the p38 MAPK signaling pathway. J Immunol. 2012, Jul, 15;189(2):813\u201318. https:\/\/doi.org\/10.4049\/JIMMUNOL.1102041 PubMed PMID: 22675202.","journal-title":"J Immunol"},{"issue":"1","key":"8209_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1743-422X-8-157","volume":"8","author":"LJ Zhao","year":"2011","unstructured":"Zhao LJ, Hua X, He SF, Ren H, Qi ZT. Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J. 2011;8(1):157. https:\/\/doi.org\/10.1186\/1743-422X-8-157 PubMed PMID: 21466707.","journal-title":"Virol J"},{"issue":"2","key":"8209_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1189\/JLB.2A0114-059RR","volume":"97","author":"M Jiang","year":"2015","unstructured":"Jiang M, O\u00a8sterlund P, Fagerlund R, Rios DN, Hoffmann A, Poranen MM, et al. MAP kinase p38\u03b1 regulates type III interferon (IFN-\u03bb1) gene expression in human monocyte-derived dendritic cells in response to RNA stimulation. J Leukoc Biol. 2015, Feb, 1;97(2):307\u201320. https:\/\/doi.org\/10.1189\/JLB.2A0114-059RR PubMed PMID: 25473098.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"8209_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/EMI.2014.51","volume":"3","author":"A Egli","year":"2014","unstructured":"Egli A, Santer DM, O\u2019Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerging Microbes Infections. 2014, Jul, 2;3(1):1\u201312. https:\/\/doi.org\/10.1038\/EMI.2014.51 PubMed PMID: 26038748.","journal-title":"Emerging Microbes Infections"},{"key":"8209_CR25","doi-asserted-by":"publisher","unstructured":"Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-\u03bb contributes to innate immunity of mice against influenza a virus but not against hepatotropic viruses. PLoS Pathog. 2008, Sep;4(9):e1000151. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1000151 PubMed PMID: 18787692.","DOI":"10.1371\/JOURNAL.PPAT.1000151"},{"issue":"1","key":"8209_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/eji.201444903","volume":"45","author":"de Groen Ra","year":"2015","unstructured":"de Groen Ra, Boltjes A, Hou J, Liu BS, Mcphee F, Friborg J, et al. IFN-\u03bb-mediated IL-12 production in macrophages induces IFN-\u03b3 production in human NK cells. Eur J Immunol. 2015, Jan, 1;45(1):250\u201359. https:\/\/doi.org\/10.1002\/eji.201444903 PubMed PMID: 25316442.","journal-title":"Eur J Immunol"},{"issue":"10","key":"8209_CR27","doi-asserted-by":"publisher","first-page":"476246","DOI":"10.3389\/fimmu.2019.02674","volume":"10","author":"SA Read","year":"2019","unstructured":"Read SA, Wijaya R, Ramezani-Moghadam M, Tay E, Schibeci S, Liddle C, et al. Macrophage coordination of the interferon lambda immune response. Front Immunol. 2019, Nov;10(10):476246. https:\/\/doi.org\/10.3389\/fimmu.2019.02674 PubMed PMID: 31798594.","journal-title":"Front Immunol"},{"key":"8209_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/731023","volume":"2013","author":"R G\u00fcnthner","year":"2013","unstructured":"G\u00fcnthner R, Anders HJ. Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflammation. 2013;2013:1\u20138. https:\/\/doi.org\/10.1155\/2013\/731023 PubMed PMID: 24379524.","journal-title":"Mediators Inflammation"},{"issue":"8","key":"8209_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/S41590-019-0408-Z","volume":"20","author":"EA Hemann","year":"2019","unstructured":"Hemann EA, Green R, Turnbull JB, Langlois RA, Savan R, Gale M. Interferon-\u03bb modulates dendritic cells to facilitate T cell immunity during infection with influenza a virus. Nat Immunol. 2019, Aug, 1;20(8):1035. https:\/\/doi.org\/10.1038\/S41590-019-0408-Z PubMed PMID: 31235953.","journal-title":"Nat Immunol"},{"issue":"11","key":"8209_CR30","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1182\/BLOOD-2005-10-4129","volume":"107","author":"FJD Mennechet","year":"2006","unstructured":"Mennechet FJD, Uz\u00e9 G. Interferon-\u03bb\u2013treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006, Jun, 1;107(11):4417\u201323. https:\/\/doi.org\/10.1182\/BLOOD-2005-10-4129 PubMed PMID: 16478884.","journal-title":"Blood"},{"issue":"3","key":"8209_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1189\/JLB.0812395","volume":"93","author":"H Dickensheets","year":"2012","unstructured":"Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. Interferon-lambda (IFN-\u03bb) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol. 2012, Dec, 20;93(3):377. https:\/\/doi.org\/10.1189\/JLB.0812395 PubMed PMID: 23258595.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"8209_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4161\/CBT.7.7.6192","volume":"7","author":"SG Maher","year":"2008","unstructured":"Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFN-\u03b1 and IFN-\u03bb differ in their antiproliferative effects and duration of JAK\/STAT signaling activity. Cancer Biol Ther. 2008;7(7):1109. https:\/\/doi.org\/10.4161\/CBT.7.7.6192 PubMed PMID: 18698163.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"8209_CR33","doi-asserted-by":"publisher","first-page":"108211","DOI":"10.1016\/J.CELREP.2020.108211","volume":"33","author":"M Syedbasha","year":"2020","unstructured":"Syedbasha M, Bonfiglio F, Linnik J, Stuehler C, W\u00fcthrich D, Egli A. Interferon-\u03bb enhances the differentiation of naive B cells into plasmablasts via the mTORC1 pathway. Cell Rep. 2020, Oct, 6;33(1):108211. https:\/\/doi.org\/10.1016\/J.CELREP.2020.108211 PubMed PMID: 33027651.","journal-title":"Cell Rep"},{"issue":"6","key":"8209_CR34","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","volume":"4","author":"V Mesev E","year":"2019","unstructured":"Mesev E V, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat Microbiol. 2019, Jun, 1;4(6):914. https:\/\/doi.org\/10.1038\/s41564-019-0421-x PubMed PMID: 30936491.","journal-title":"Nat Microbiol"},{"issue":"34","key":"8209_CR35","doi-asserted-by":"publisher","first-page":"13925","DOI":"10.1074\/JBC.R116.774745","volume":"292","author":"DS Green","year":"2017","unstructured":"Green DS, Young HA, Valencia JC. Current prospects of type II interferon \u03b3 signaling and autoimmunity. J Biol Chem. 2017, Aug, 25;292(34):13925. https:\/\/doi.org\/10.1074\/JBC.R116.774745 PubMed PMID: 28652404.","journal-title":"J Biol Chem"},{"key":"8209_CR36","doi-asserted-by":"publisher","unstructured":"Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-Lambda (IFN-\u03bb) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008, Mar;4(3):e1000017. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1000017 PubMed PMID: 18369468.","DOI":"10.1371\/JOURNAL.PPAT.1000017"},{"issue":"29","key":"8209_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cytogfr.2016.02.005","volume":"29","author":"TS Cohen","year":"2016","unstructured":"Cohen TS, Parker D. Microbial pathogenesis and type III interferons. Cytokine Growth Factor Rev. 2016, Jun;29(29):45. https:\/\/doi.org\/10.1016\/j.cytogfr.2016.02.005 PubMed PMID: 26987613.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"8209_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/J.COVIRO.2011.10.026","volume":"1","author":"M Swiecki","year":"2011","unstructured":"Swiecki M, Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. Curr Opin Virol. 2011;1(6):463. https:\/\/doi.org\/10.1016\/J.COVIRO.2011.10.026 PubMed PMID: 22440910.","journal-title":"Curr Opin Virol"},{"issue":"1","key":"8209_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000495172","volume":"51","author":"JH Zhou","year":"2018","unstructured":"Zhou JH, Wang YN, Chang QY, Ma P, Hu Y, Cao X. Type III interferons in viral infection and antiviral immunity. Cell Physiol Biochem. 2018;51(1):173\u201385. https:\/\/doi.org\/10.1159\/000495172 PubMed PMID: 30439714.","journal-title":"Cell Physiol Biochem"},{"key":"8209_CR40","doi-asserted-by":"publisher","unstructured":"Dalskov L, Gad HH, Hartmann R. Viral recognition and the antiviral interferon response. Embo J. 2023, Jul, 17;42(14):e112907. https:\/\/doi.org\/10.15252\/embj.2022112907 PubMed PMID: 37367474.","DOI":"10.15252\/embj.2022112907"},{"issue":"9\u201310","key":"8209_CR41","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.imbio.2008.07.020","volume":"213","author":"S Stockinger","year":"2008","unstructured":"Stockinger S, Decker T. Novel functions of type I interferons revealed by infection studies with listeria monocytogenes. Immunobiology. 2008, Nov, 6;213(9\u201310):889\u201397. https:\/\/doi.org\/10.1016\/j.imbio.2008.07.020 PubMed PMID: 18926303.","journal-title":"Immunobiology"},{"key":"8209_CR42","doi-asserted-by":"publisher","unstructured":"Horvath CM. The Jak-STAT pathway stimulated by interferon \u03b1 or interferon \u03b2. Sci STKE. 2004, Nov, 23;2004(260). https:\/\/doi.org\/10.1126\/STKE.2602004TR10.","DOI":"10.1126\/STKE.2602004TR10"},{"issue":"9","key":"8209_CR43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1089\/JIR.2015.0008","volume":"35","author":"EA Voigt","year":"2015","unstructured":"Voigt EA, Yin J. Kinetic differences and synergistic antiviral effects between type I and type III interferon signaling indicate pathway independence. J Interferon Cytokine Res. 2015, Sep, 1;35(9):734. https:\/\/doi.org\/10.1089\/JIR.2015.0008 PubMed PMID: 25938799.","journal-title":"J Interferon Cytokine Res"},{"issue":"9","key":"8209_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/S41577-018-0029-Z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018, Sep, 1;18(9):545. https:\/\/doi.org\/10.1038\/S41577-018-0029-Z PubMed PMID: 29921905.","journal-title":"Nat Rev Immunol"},{"issue":"SEP","key":"8209_CR45","doi-asserted-by":"publisher","first-page":"403701","DOI":"10.3389\/fimmu.2018.02061","volume":"9","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018, Sep, 11;9(SEP):403701. https:\/\/doi.org\/10.3389\/fimmu.2018.02061 PubMed PMID: 30254639.","journal-title":"Front Immunol"},{"key":"8209_CR46","doi-asserted-by":"publisher","unstructured":"Todt D, Fran\u00e7ois C, Anggakusuma A, Behrendt P, Engelmann M, L, et al. Antiviral activities of different interferon types and subtypes against hepatitis E virus replication. Antimicrob Agents Chemother. 2016, Apr, 1;60(4):2132\u201339. https:\/\/doi.org\/10.1128\/AAC.02427-15 PubMed PMID: 26787701.","DOI":"10.1128\/AAC.02427-15"},{"key":"8209_CR47","doi-asserted-by":"publisher","unstructured":"Benveniste EN, Qin H. Type I interferons as anti-inflammatory mediators. Sci STKE. 2007, Dec, 11;2007(416). https:\/\/doi.org\/10.1126\/stke.4162007pe70 PubMed PMID: 18073382.","DOI":"10.1126\/stke.4162007pe70"},{"issue":"1","key":"8209_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/S13578-023-01188-Z","volume":"13","author":"L Ji","year":"2023","unstructured":"Ji L, Li T, Chen H, Yang Y, Lu E, Liu J, et al. The crucial regulatory role of type I interferon in inflammatory diseases. Cell Biosci. 2023, Dec, 1;13(1):230. https:\/\/doi.org\/10.1186\/S13578-023-01188-Z PubMed PMID: 38124132.","journal-title":"Cell Biosci"},{"key":"8209_CR49","doi-asserted-by":"publisher","unstructured":"Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019, May, 28;6(1):e000336. https:\/\/doi.org\/10.1136\/LUPUS-2019-000336 PubMed PMID: 10.1136\/lupus-2019-000336.","DOI":"10.1136\/LUPUS-2019-000336"},{"key":"8209_CR50","doi-asserted-by":"publisher","unstructured":"Broggi A, Granucci F, Zanoni I. Type III interferons: balancing tissue tolerance and resistance to pathogen invasion. J Exp Med. 2020, Jan, 1;217(1). https:\/\/doi.org\/10.1084\/jem.20190295 PubMed PMID: 31821443.","DOI":"10.1084\/jem.20190295"},{"issue":"4","key":"8209_CR51","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/PH3040994","volume":"3","author":"J Bekisz","year":"2010","unstructured":"Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative properties of type I and type II interferon. Pharmaceuticals (Basel). 2010;3(4):994\u20131015. https:\/\/doi.org\/10.3390\/PH3040994 PubMed PMID: 20664817.","journal-title":"Pharmaceuticals (Basel)"},{"key":"8209_CR52","doi-asserted-by":"publisher","unstructured":"Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu EJ, et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021;12(1):5866\u2013. https:\/\/doi.org\/10.1038\/s41467-021-26112-2 PubMed PMID: 34620867.","DOI":"10.1038\/s41467-021-26112-2"},{"issue":"41","key":"8209_CR53","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/ONCOTARGET.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano RFV, Hunger A, Mendon\u00e7a SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249. https:\/\/doi.org\/10.18632\/ONCOTARGET.19531 PubMed PMID: 29050360.","journal-title":"Oncotarget"},{"issue":"5","key":"8209_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/CANCERS13051037","volume":"13","author":"SE Fenton","year":"2021","unstructured":"Fenton SE, Saleiro D, Platanias LC. Type I and II interferons in the anti-tumor immune response. Cancers (Basel). 2021, Mar, 1;13(5):1037. https:\/\/doi.org\/10.3390\/CANCERS13051037 PubMed PMID: 33801234.","journal-title":"Cancers (Basel)"},{"key":"8209_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/479013","volume":"2011","author":"M Tagawa","year":"2011","unstructured":"Tagawa M, Kawamura K, Li Q, Tada Y, Hiroshima K, Shimada H. A possible anticancer agent, type III interferon, activates cell Death pathways and produces Antitumor effects. Clin Dev Immunol. 2011;2011:1\u20136. https:\/\/doi.org\/10.1155\/2011\/479013 PubMed PMID: 22013482.","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"8209_CR56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/PH2030206","volume":"2","author":"RM Friedman","year":"2009","unstructured":"Friedman RM, Contente S. Interferons as therapy for viral and neoplastic diseases: from panacea to pariah to paragon. Pharmaceuticals. 2009, Dec, 1;2(3):206. https:\/\/doi.org\/10.3390\/PH2030206 PubMed PMID: 27713234.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"8209_CR57","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4049\/IMMUNOHORIZONS.2200010","volume":"7","author":"I Mart\u00ednez-Espinoza","year":"2023","unstructured":"Mart\u00ednez-Espinoza I, Guerrero-Plata A. Current landscape of IFN-\u03bb: induction, inhibition, and potential clinical applications to treat respiratory viral infections. Immunohorizons. 2023, Apr, 1;7(4):265. https:\/\/doi.org\/10.4049\/IMMUNOHORIZONS.2200010 PubMed PMID: 37071039.","journal-title":"Immunohorizons"},{"issue":"14","key":"8209_CR58","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/S00018-017-2520-2","volume":"74","author":"N Raftery","year":"2017","unstructured":"Raftery N, Stevenson NJ. Advances in anti-viral immune defence: revealing the importance of the IFN JAK\/STAT pathway. Cell Mol Life Sci. 2017, Jul, 1;74(14):2525. https:\/\/doi.org\/10.1007\/S00018-017-2520-2 PubMed PMID: 28432378.","journal-title":"Cell. Mol. Life Sci"},{"issue":"1","key":"8209_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/349575","volume":"2011","author":"A Lasfar","year":"2011","unstructured":"Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a New sword in cancer immunotherapy. Clin Dev Immunol. 2011, Jan, 1;2011(1):1\u201311. https:\/\/doi.org\/10.1155\/2011\/349575 PubMed PMID: 22190970.","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"8209_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/J.CANLET.2011.07.004","volume":"311","author":"X Hui","year":"2011","unstructured":"Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B. Antitumor activities of recombinant human interferon (IFN)-\u03bb1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. 2011, Dec, 8;311(2):141\u201351. https:\/\/doi.org\/10.1016\/J.CANLET.2011.07.004 PubMed PMID: 21872388.","journal-title":"Cancer Lett"},{"issue":"2","key":"8209_CR61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/J.JACI.2023.04.022","volume":"152","author":"R Siebeler","year":"2023","unstructured":"Siebeler R, de Winther MPJ, Hoeksema MA. The regulatory landscape of macrophage interferon signaling in inflammation. J Allergy Clin Immunol Pract. 2023, Aug, 1;152(2):326\u201337. https:\/\/doi.org\/10.1016\/J.JACI.2023.04.022 PubMed PMID: 37271317.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"8209_CR62","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/S41584-021-00606-1","volume":"17","author":"RR Goel","year":"2021","unstructured":"Goel RR, Kotenko S V, Kaplan MJ. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat Rev Rheumatol. 2021, Jun, 1;17(6):349. https:\/\/doi.org\/10.1038\/S41584-021-00606-1 PubMed PMID: 33907323.","journal-title":"Nat Rev Rheumatol"},{"key":"8209_CR63","doi-asserted-by":"publisher","unstructured":"Rauch I, M\u00fcller M, Decker T. The regulation of inflammation by interferons and their STATs. JAK-STAT. 2013, Jan;2(1):e23820. https:\/\/doi.org\/10.4161\/JKST.23820 PubMed PMID: 24058799.","DOI":"10.4161\/JKST.23820"},{"key":"8209_CR64","doi-asserted-by":"publisher","unstructured":"Goel RR, Wang X, O\u2019Neil LJ, Nakabo S, Hasneen K, Gupta S, et al. Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Proc Natl Acad Sci. 2020 Mar 10: 5409\u201319. https:\/\/doi.org\/10.1073\/PNAS.1916897117 117(10) PubMed PMID: 32094169.","DOI":"10.1073\/PNAS.1916897117"},{"issue":"8","key":"8209_CR65","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.4049\/JIMMUNOL.178.8.5086","volume":"178","author":"M Numasaki","year":"2007","unstructured":"Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, et al. IL-28 Elicits Antitumor responses against Murine Fibrosarcoma. J Immunol. 2007, Apr, 15;178(8):5086\u201398. https:\/\/doi.org\/10.4049\/JIMMUNOL.178.8.5086 PubMed PMID: 17404291.","journal-title":"J Immunol"},{"issue":"FEB","key":"8209_CR66","doi-asserted-by":"publisher","first-page":"242342","DOI":"10.3389\/fimmu.2017.00119","volume":"8","author":"M Syedbasha","year":"2017","unstructured":"Syedbasha M, Egli A. Interferon lambda: modulating immunity in infectious diseases. Front Immunol. 2017, Feb 28;8(FEB):242342. https:\/\/doi.org\/10.3389\/fimmu.2017.00119.","journal-title":"Front Immunol"},{"issue":"15","key":"8209_CR67","doi-asserted-by":"publisher","first-page":"1338096","DOI":"10.3389\/fimmu.2024.1338096","volume":"15","author":"YG Liu","year":"2024","unstructured":"Liu YG, Jin SW, Zhang SS, Xia TJ, Liao YH, Pan R-L, et al. Interferon lambda in respiratory viral infection: immunomodulatory functions and antiviral effects in epithelium. Front Immunol. 2024, Mar;15(15):1338096. https:\/\/doi.org\/10.3389\/fimmu.2024.1338096 PubMed PMID: 38495892.","journal-title":"Front Immunol"},{"issue":"9","key":"8209_CR68","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","volume":"80","author":"N Ank","year":"2006","unstructured":"Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-\u03bb), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006, May;80(9):4501. https:\/\/doi.org\/10.1128\/JVI.80.9.4501-4509.2006 PubMed PMID: 16611910.","journal-title":"J Virol"},{"issue":"8","key":"8209_CR69","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/v13081602","volume":"13","author":"M Plotnikova","year":"2021","unstructured":"Plotnikova M, Lozhkov A, Romanovskaya-Romanko E, Baranovskaya I, Sergeeva M, K\u0430\u0430 K, et al. IFN-\u03bb1 displays various levels of antiviral activity in vitro in a select panel of RNA viruses. Viruses. 2021, Aug, 1;13(8):1602. https:\/\/doi.org\/10.3390\/v13081602 PubMed PMID: 34452467.","journal-title":"Viruses"},{"issue":"5","key":"8209_CR70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41590-019-0345-x","volume":"20","author":"L Ye","year":"2019","unstructured":"Ye L, Schnepf D, Becker J, Ebert K, Tanriver Y, Bernasconi V, et al. Interferon-\u03bb enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat Immunol. 2019, May, 1;20(5):593\u2013601. https:\/\/doi.org\/10.1038\/s41590-019-0345-x PubMed PMID: 30886417.","journal-title":"Nat Immunol"},{"issue":"OCT","key":"8209_CR71","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3389\/fimmu.2019.02394","volume":"10","author":"L Li","year":"2019","unstructured":"Li L, Xue M, Fu F, Yin L, Feng L, Liu P. Ifn-lambda 3 mediates antiviral protection against porcine epidemic diarrhea virus by inducing a distinct antiviral transcript profile in porcine intestinal epithelia. Front Immunol. 2019;10(OCT):2394. https:\/\/doi.org\/10.3389\/fimmu.2019.02394 PubMed PMID: 31681286.","journal-title":"Front Immunol"},{"key":"8209_CR72","doi-asserted-by":"publisher","unstructured":"Sojati J, Parks OB, Zhang Y, Walters S, Lan J, Eddens T, et al. IFN-\u03bb drives distinct lung immune landscape changes and antiviral responses in human metapneumovirus infection. mBio. 2024, May, 1;15(5). https:\/\/doi.org\/10.1128\/MBIO.00550-24 PubMed PMID: 38530032.","DOI":"10.1128\/MBIO.00550-24"},{"key":"8209_CR73","doi-asserted-by":"publisher","unstructured":"Zanoni I, Granucci F, Broggi A. Interferon (IFN)-\u03bb takes the helm: immunomodulatory roles of type III IFNs. Front Immunol. 2017, Nov, 2;8(NOV). https:\/\/doi.org\/10.3389\/FIMMU.2017.01661.","DOI":"10.3389\/FIMMU.2017.01661"},{"issue":"23","key":"8209_CR74","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1182\/BLOOD-2008-09-179507","volume":"113","author":"J Dai","year":"2009","unstructured":"Dai J, Megjugorac NJ, Gallagher GE, Yu RYL, Gallagher G. IFN-\u03bb1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood. 2009;113(23):5829\u201338. https:\/\/doi.org\/10.1182\/BLOOD-2008-09-179507 PubMed PMID: 19346497.","journal-title":"Blood"},{"issue":"3","key":"8209_CR75","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/SJ.GENE.6364382","volume":"8","author":"WJ Jordan","year":"2007","unstructured":"Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al. Human interferon lambda-1 (IFN-\u03bb1\/IL-29) modulates the Th1\/Th2 response. Genes Immun. 2007, Apr;8(3):254\u201361. https:\/\/doi.org\/10.1038\/SJ.GENE.6364382 PubMed PMID: 17361203.","journal-title":"Genes Immun"},{"issue":"3","key":"8209_CR76","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/EJI.200324610","volume":"34","author":"EM Coccia","year":"2004","unstructured":"Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and \u03bb interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol. 2004, Mar;34(3):796\u2013805. https:\/\/doi.org\/10.1002\/EJI.200324610 PubMed PMID: 14991609.","journal-title":"Eur J Immunol"},{"issue":"1","key":"8209_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-58220-8","volume":"16","author":"C Sakref","year":"2025","unstructured":"Sakref C, Saby A, Rodriguez C, Ardin M, Moudombi L, Doffin AC, et al. Type III interferon primes pDcs for TLR7 activation and antagonizes immune suppression mediated by TGF-\u03b2 and PGE2. Nat Commun. 2025;16(1):1\u201318. https:\/\/doi.org\/10.1038\/s41467-025-58220-8 PubMed PMID: 40155377.","journal-title":"Nat Commun"},{"key":"8209_CR78","doi-asserted-by":"publisher","unstructured":"Wang B, Zhou B, Chen J, Sun X, Yang W, Yang T, et al. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. J Immunother Cancer. 2024, Apr, 8;12(4):e007808. https:\/\/doi.org\/10.1136\/JITC-2023-007808 PubMed PMID: 10.1136\/jitc-2023-007808.","DOI":"10.1136\/JITC-2023-007808"},{"issue":"2","key":"8209_CR79","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/S41435-022-00164-W","volume":"23","author":"M De","year":"2022","unstructured":"De M, Bhushan A, Grubbe WS, Roy S, Mendoza JL, Chinnaswamy S. Distinct molecular phenotypes involving several human diseases are induced by IFN-\u03bb3 and IFN-\u03bb4 in monocyte-derived macrophages. Genes Immun. 2022, Apr, 1;23(2):73\u201384. https:\/\/doi.org\/10.1038\/S41435-022-00164-W PubMed PMID: 35115664.","journal-title":"Genes Immun"},{"issue":"1","key":"8209_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-023-04453-4","volume":"21","author":"ZZ Wang","year":"2023","unstructured":"Wang ZZ, Wen XL, Wang N, Li XH, Guo Y, Zhu X, et al. Portraying the dark side of endogenous IFN-\u03bb for promoting cancer progression and immunoevasion in pan-cancer. J Transl Med. 2023, Dec, 1;21(1):1\u201318. https:\/\/doi.org\/10.1186\/s12967-023-04453-4 PubMed PMID: 37697300.","journal-title":"J Transl Med"},{"issue":"7","key":"8209_CR81","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00262-010-0831-3","volume":"59","author":"W Abushahba","year":"2010","unstructured":"Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010, Jul;59(7):1059. https:\/\/doi.org\/10.1007\/s00262-010-0831-3 PubMed PMID: 20217081.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"8209_CR82","doi-asserted-by":"publisher","first-page":"2284483","DOI":"10.1080\/2162402X.2023.2284483","volume":"12","author":"J Bl\u00fcmke","year":"2023","unstructured":"Bl\u00fcmke J, Bauer M, Vaxevanis C, Wilfer A, Mandelboim O, Wickenhauser C, et al. Identification and characterization of the anti-viral interferon lambda 3 as direct target of the Epstein-Barr virus microRNA-BART7-3p. Oncoimmunology. 2023;12(1):2284483. https:\/\/doi.org\/10.1080\/2162402X.2023.2284483 PubMed PMID: 38126030.","journal-title":"Oncoimmunology"},{"key":"8209_CR83","doi-asserted-by":"publisher","unstructured":"Hubert M, Gobbini E, Couillault C, Manh TPV, Doffin AC, Berthet J, et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci Immunol. 2020, Apr, 17;5(46). https:\/\/doi.org\/10.1126\/SCIIMMUNOL.AAV3942 PubMed PMID: 32303573.","DOI":"10.1126\/SCIIMMUNOL.AAV3942"},{"issue":"13","key":"8209_CR84","doi-asserted-by":"publisher","first-page":"974793","DOI":"10.3389\/fimmu.2022.974793","volume":"13","author":"H Hua","year":"2023","unstructured":"Hua H, He W, Chen N, He Y, Wu G, Ye F, et al. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. Front Immunol. 2023, Jan;13(13):974793. https:\/\/doi.org\/10.3389\/fimmu.2022.974793 PubMed PMID: 36700211.","journal-title":"Front Immunol"},{"issue":"3","key":"8209_CR85","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3892\/or.2016.4925","volume":"36","author":"X Bu","year":"2016","unstructured":"Bu X, Li M, Zhao Y, Liu S, Wang M, Ge J, et al. Genetically engineered Newcastle disease virus expressing human interferon-\u03bb1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1\/Th2 immune response. Oncol Rep. 2016, Sep, 1;36(3):1393\u2013402. https:\/\/doi.org\/10.3892\/or.2016.4925 PubMed PMID: 27430534.","journal-title":"Oncol Rep"},{"key":"8209_CR86","doi-asserted-by":"publisher","unstructured":"Baldridge MT, Lee S, Brown JJ, McAllister N, Urbanek K, Dermody TS, et al. Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus. J Virol. 2017, Apr;91(7):e02079\u201316. https:\/\/doi.org\/10.1128\/jvi.02079-16 PubMed PMID: 28077655.","DOI":"10.1128\/jvi.02079-16"},{"key":"8209_CR87","doi-asserted-by":"publisher","unstructured":"S\u00f8rensen MD, Olsen RFS, Burton M, Kavan S, Petterson SA, Thomassen M, et al. Microglia induce an interferon-stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide. Neuropathol Appl Neurobio. 2024, Dec, 1;50(6). https:\/\/doi.org\/10.1111\/NAN.13016 PubMed PMID: 39558550.","DOI":"10.1111\/NAN.13016"},{"issue":"11","key":"8209_CR88","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3390\/BIOMEDICINES10112965","volume":"10","author":"LJ Castro-Mu\u00f1oz","year":"2022","unstructured":"Castro-Mu\u00f1oz LJ, Rocha-Zavaleta L, Lizano M, Ram\u00edrez-Alc\u00e1ntara KM, Madrid-Marina V, Manzo-Merino J. Alteration of the IFN-Pathway by human papillomavirus proteins: antiviral immune response evasion mechanism. Biomedicines. 2022, Nov, 1;10(11):2965. https:\/\/doi.org\/10.3390\/BIOMEDICINES10112965 PubMed PMID: 36428532.","journal-title":"Biomedicines"},{"issue":"3","key":"8209_CR89","first-page":"24","volume":"5","author":"SM Russell","year":"2013","unstructured":"Russell SM, Angell TE, Lechner MG, Liebertz DJ, Correa AJ, Sinha UK, et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol. 2013, Feb, 27;5(3):24. PubMed PMID: 24723971.","journal-title":"Head Neck Oncol"},{"issue":"3","key":"8209_CR90","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000370113","volume":"7","author":"A Stiff","year":"2015","unstructured":"Stiff A, Carson W. Investigations of interferon-lambda for the treatment of cancer. J Innate Immun. 2015, May, 6;7(3):243. https:\/\/doi.org\/10.1159\/000370113 PubMed PMID: 25661266.","journal-title":"J Innate Immun"},{"issue":"11","key":"8209_CR91","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1089\/JIR.2014.0161","volume":"35","author":"OO Onabajo","year":"2015","unstructured":"Onabajo OO, Porter-Gill P, Paquin A, Rao N, Liu L, Tang W, et al. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell Death in human hepatic cells. J Interferon Cytokine Res. 2015, Nov, 1;35(11):888. https:\/\/doi.org\/10.1089\/JIR.2014.0161 PubMed PMID: 26134097.","journal-title":"J Interferon Cytokine Res"},{"issue":"8","key":"8209_CR92","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1096\/FJ.14-250704","volume":"28","author":"S Tian","year":"2014","unstructured":"Tian S, Hui X, Fan Z, Li Q, Zhang J, Yang X, et al. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-\u03bb1 or PEG-interferon-\u03bb1. The FASEB J. 2014;28(8):3528\u201339. https:\/\/doi.org\/10.1096\/FJ.14-250704 PubMed PMID: 24769671.","journal-title":"The FASEB J"},{"issue":"14","key":"8209_CR93","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","volume":"28","author":"G Corradi","year":"2022","unstructured":"Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Fontana MC, et al. Release of IFN\u03b3 by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. Clin Cancer Res. 2022, Jul, 15;28(14):3141\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3594 PubMed PMID: 35349670.","journal-title":"Clin Cancer Res"},{"key":"8209_CR94","doi-asserted-by":"publisher","unstructured":"Huo W, Chen M, Chang C, Yu J, Chen D, Wang R. Modulation of the tumor immune microenvironment by interferon regulatory Factor 8 enhances immunotherapy in lung adenocarcinoma. Sci Rep. 2025, Mar 20;15(1):9565\u2013. https:\/\/doi.org\/10.1038\/s41598-025-94424-0 PubMed PMID: 40113982.","DOI":"10.1038\/s41598-025-94424-0"},{"key":"8209_CR95","doi-asserted-by":"publisher","unstructured":"Esparza M, El Zahed SS, Karakus U, Niederstrasser H, Gao B, Batten K, et al. Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells. J Virol. 2025, Jun, 17;99(6). https:\/\/doi.org\/10.1128\/jvi.00469-25 PubMed PMID: 40434103.","DOI":"10.1128\/jvi.00469-25"},{"issue":"2","key":"8209_CR96","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/gene.2008.87","volume":"10","author":"C Dellgren","year":"2009","unstructured":"Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-\u03bb3 is a potent member of the type III interferon family. Genes Immun. 2009, Jan, 1;10(2):125\u201331. https:\/\/doi.org\/10.1038\/gene.2008.87 PubMed PMID: 18987645.","journal-title":"Genes Immun"},{"key":"8209_CR97","doi-asserted-by":"publisher","unstructured":"Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM. A role for IFN-\u03bb1 in multiple myeloma B cell growth. In: Leukemia : official journal of the leukemia society of America, leukemia research fund. Vol. 22(12). UK; 2008. p. 2240. https:\/\/doi.org\/10.1038\/leu.2008.263 PubMed PMID: 18830264.","DOI":"10.1038\/leu.2008.263"},{"issue":"4","key":"8209_CR98","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/1873-3468.15041","volume":"599","author":"LA Novotny","year":"2025","unstructured":"Novotny LA, Meissner EG. Expression and function of interferon lambda receptor 1 variants. FEBS Lett. 2025, Feb, 1;599(4):466. https:\/\/doi.org\/10.1002\/1873-3468.15041 PubMed PMID: 39435588.","journal-title":"FEBS Lett"},{"issue":"12","key":"8209_CR99","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/PATHOGENS9120989","volume":"9","author":"AA Lozhkov","year":"2020","unstructured":"Lozhkov AA, Klotchenko SA, Ramsay ES, Moshkoff HD, Moshkoff DA, Vasin A V, et al. The key roles of interferon lambda in human molecular defense against respiratory viral infections. Pathogens. 2020, Dec, 1;9(12):989. https:\/\/doi.org\/10.3390\/PATHOGENS9120989 PubMed PMID: 33255985.","journal-title":"Pathogens"},{"issue":"8","key":"8209_CR100","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.4049\/JIMMUNOL.1301705","volume":"192","author":"I Misumi","year":"2014","unstructured":"Misumi I, Whitmire JK. IFN-\u03bb exerts opposing effects on T cell responses depending on the chronicity of the virus infection. J Immunol. 2014, Apr, 15;192(8):3596. https:\/\/doi.org\/10.4049\/JIMMUNOL.1301705 PubMed PMID: 24646741.","journal-title":"J Immunol"},{"key":"8209_CR101","doi-asserted-by":"publisher","unstructured":"Solstad AD, Denz PJ, Kenney AD, Mahfooz NS, Speaks S, Gong Q, et al. IFN-\u03bb uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN. JCI Insight. 2024, Jul, 8;9(13). https:\/\/doi.org\/10.1172\/JCI.INSIGHT.171830 PubMed PMID: 0.","DOI":"10.1172\/JCI.INSIGHT.171830"},{"issue":"31","key":"8209_CR102","doi-asserted-by":"publisher","first-page":"49259","DOI":"10.18632\/ONCOTARGET.10272","volume":"7","author":"A Lasfar","year":"2016","unstructured":"Lasfar A, de la TA, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, et al. Concerted action of IFN-\u03b1 and IFN-\u03bb induces local NK cell immunity and halts cancer growth. Oncotarget. 2016, Jun, 24;7(31):49259\u201367. https:\/\/doi.org\/10.18632\/ONCOTARGET.10272 PubMed PMID: 27363032.","journal-title":"Oncotarget"},{"key":"8209_CR103","doi-asserted-by":"publisher","first-page":"1525083","DOI":"10.3389\/fimmu.2024.1525083","volume":"15","author":"SH Godsk","year":"2025","unstructured":"Godsk SH, Jensen CMS, Larsen TV, Ahrenfeldt J, Gammelgaard KR, Jakobsen MR. IFN\u03bb1 is a STING-dependent mediator of DNA damage and induces immune activation in lung cancer. Front Immunol. 2025;15:1525083. https:\/\/doi.org\/10.3389\/fimmu.2024.1525083 PubMed PMID: 40012911.","journal-title":"Front Immunol"},{"issue":"1","key":"8209_CR104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3892\/or.2014.3185","volume":"32","author":"Z Gao","year":"2014","unstructured":"Gao Z, Zhu M, Wu Y, Gao P, Qin Z, Wang H. Interferon-\u03bb1 induces G1 phase cell cycle arrest and apoptosis in gastric carcinoma cells in vitro. Oncol Rep. 2014, Jul, 1;32(1):199\u2013204. https:\/\/doi.org\/10.3892\/or.2014.3185 PubMed PMID: 24840622.","journal-title":"Oncol Rep"},{"key":"8209_CR105","doi-asserted-by":"publisher","unstructured":"Ha JL, Kaser E, Guan T, Mayberry TG, Smith LA, D\u2019mello K, et al. Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1. Med Oncol. 2024, Mar, 1;41(3). https:\/\/doi.org\/10.1007\/S12032-023-02276-3 PubMed PMID: 38281234.","DOI":"10.1007\/S12032-023-02276-3"},{"key":"8209_CR106","doi-asserted-by":"publisher","unstructured":"Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, et al. NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci USA. 2015, May, 5;112(18):E2376\u201384. https:\/\/doi.org\/10.1073\/PNAS.1424241112 PubMed PMID: 25901316.","DOI":"10.1073\/PNAS.1424241112"},{"issue":"1","key":"8209_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-06381-z","volume":"15","author":"SJ Yang","year":"2024","unstructured":"Yang SJ, Chang ST, Chang KC, Lin BW, Chang KY, Liu YW, et al. Neutralizing IL-16 enhances the efficacy of targeting Aurora-A therapy in colorectal cancer with high lymphocyte infiltration through restoring anti-tumor immunity. Cell Death Dis. 2024, Jan, 1;15(1):1\u201314. https:\/\/doi.org\/10.1038\/s41419-023-06381-z PubMed PMID: 38291041.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8209_CR108","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/S12943-025-02353-3","volume":"24","author":"P Vats","year":"2025","unstructured":"Vats P, Saini C, Baweja B, Srivastava SK, Kumar A, Kushwah AS, et al. Aurora kinases signaling in cancer: from molecular perception to targeted therapies. Mol Cancer. 2025, Dec, 1;24(1):180. https:\/\/doi.org\/10.1186\/S12943-025-02353-3 PubMed PMID: 40533769.","journal-title":"Mol Cancer"},{"issue":"2","key":"8209_CR109","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/2767-9764.CRC-23-0432","volume":"4","author":"L Choy","year":"2024","unstructured":"Choy L, Norris S, Wu X, Kolumam G, Firestone A, Settleman J, et al. Inhibition of Aurora kinase induces endogenous retroelements to induce a type I\/III IFN response via RIG-I. Cancer Res Commun. 2024, Feb, 1;4(2):540\u201355. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0432 PubMed PMID: 38358346.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"8209_CR110","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/S12935-025-03963-Z","volume":"25","author":"K Zolfaghari","year":"2025","unstructured":"Zolfaghari K, Yazdi M, Mohammadioun S, Tajafrooz F, Malekfarnood H, Saleki K, et al. Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers. Cancer Cell Int. 2025, Oct, 3;25(1):324. https:\/\/doi.org\/10.1186\/S12935-025-03963-Z PubMed PMID: 41044775.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"8209_CR111","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/J.1349-7006.2011.02079.X","volume":"102","author":"H Fujie","year":"2011","unstructured":"Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci. 2011, Nov;102(11):1977. https:\/\/doi.org\/10.1111\/J.1349-7006.2011.02079.X PubMed PMID: 21883692.","journal-title":"Cancer Sci"},{"issue":"1","key":"8209_CR112","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/J.IJROBP.2020.02.016","volume":"108","author":"RSA Goedegebuure","year":"2020","unstructured":"Goedegebuure RSA, Vonk C, Kooij LP, Derks S, Thijssen VLJL. Combining Radiation therapy with interferons: back to the future. Int J Multiling Radiat Oncol*Biol*Phys. 2020, Sep, 1;108(1):56\u201369. https:\/\/doi.org\/10.1016\/J.IJROBP.2020.02.016 PubMed PMID: 32068114.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"204","key":"8209_CR113","doi-asserted-by":"publisher","first-page":"106974","DOI":"10.1016\/J.EJPS.2024.106974","volume":"204","author":"SG Tilden","year":"2025","unstructured":"Tilden SG, Ricco MH, Hemann EA, Anchordoquy TJ. Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy. Eur J Pharm Sci. 2025, Jan;204(204):106974. https:\/\/doi.org\/10.1016\/J.EJPS.2024.106974 PubMed PMID: 39608735.","journal-title":"Eur J Pharm Sci"},{"issue":"JUN","key":"8209_CR114","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/FIMMU.2017.00749","volume":"8","author":"S Lee","year":"2017","unstructured":"Lee S, Baldridge MT. Interferon-Lambda: a potent regulator of intestinal viral infections. Front Immunol. 2017, Jun, 30;8(JUN):749. https:\/\/doi.org\/10.3389\/FIMMU.2017.00749 PubMed PMID: 28713375.","journal-title":"Front Immunol"},{"issue":"DEC","key":"8209_CR115","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/FIMMU.2016.00598","volume":"7","author":"A Lasfar","year":"2016","unstructured":"Lasfar A, Zloza A, de la Torre A, Cohen-Solal KA. IFN-\u03bb: a New inducer of local immunity against cancer and infections. Front Immunol. 2016;7(DEC):598. https:\/\/doi.org\/10.3389\/FIMMU.2016.00598 PubMed PMID: 28018361.","journal-title":"Front Immunol"},{"key":"8209_CR116","doi-asserted-by":"publisher","unstructured":"Cheemarla NR, Watkins TA, Mihaylova VT, Wang B, Zhao D, Wang G, et al. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J Exp Med. 2021, Jun, 15;218(8):e20210583. https:\/\/doi.org\/10.1084\/JEM.20210583 PubMed PMID: 34128960.","DOI":"10.1084\/JEM.20210583"},{"issue":"31","key":"8209_CR117","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cytogfr.2016.08.001","volume":"31","author":"CM Berry","year":"2016","unstructured":"Berry CM. Understanding interferon subtype therapy for viral infections: harnessing the power of the innate immune system. Cytokine Growth Factor Rev. 2016, Oct;31(31):83\u201390. https:\/\/doi.org\/10.1016\/j.cytogfr.2016.08.001 PubMed PMID: 27544015.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"8209_CR118","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.4049\/JIMMUNOL.180.4.2474","volume":"180","author":"N Ank","year":"2008","unstructured":"Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-\u03bb\/IL-28) in TLR-Induced antiviral activity. J Immunol. 2008, Feb, 15;180(4):2474\u201385. https:\/\/doi.org\/10.4049\/JIMMUNOL.180.4.2474 PubMed PMID: 18250457.","journal-title":"J Immunol"},{"key":"8209_CR119","doi-asserted-by":"publisher","unstructured":"Peterson ST, Kennedy EA, Brigleb PH, Taylor GM, Urbanek K, Bricker TL, et al. Disruption of type III interferon (IFN) genes Ifnl2 and Ifnl3 recapitulates loss of the type III IFN receptor in the mucosal antiviral response. J Virol. 2019, Nov, 15;93(22):e01073\u201319. https:\/\/doi.org\/10.1128\/JVI.01073-19 PubMed PMID: 31462571.","DOI":"10.1128\/JVI.01073-19"},{"issue":"2","key":"8209_CR120","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1165\/rcmb.2018-0021OC","volume":"60","author":"D Ahn","year":"2019","unstructured":"Ahn D, Wickersham M, Riquelme S, Prince A. The effects of IFN-\u03bb on epithelial barrier function contribute to Klebsiella pneumoniae ST258 pneumonia. Am J Respir Cell Mol Biol. 2019, Feb, 1;60(2):158\u201366. https:\/\/doi.org\/10.1165\/rcmb.2018-0021OC PubMed PMID: 30183325.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"8209_CR121","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2353\/ajpath.2007.060789","volume":"170","author":"CA L\u00e1zaro","year":"2007","unstructured":"L\u00e1zaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol. 2007;170(2):478\u201389. https:\/\/doi.org\/10.2353\/ajpath.2007.060789 PubMed PMID: 17255316.","journal-title":"Am J Pathol"},{"issue":"6","key":"8209_CR122","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","volume":"79","author":"MD Robek","year":"2005","unstructured":"Robek MD, Boyd BS, Chisari F V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005, Mar, 15;79(6):3851\u201354. https:\/\/doi.org\/10.1128\/JVI.79.6.3851-3854.2005 PubMed PMID: 15731279.","journal-title":"J Virol"},{"issue":"1\u20132","key":"8209_CR123","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.virusres.2007.03.006","volume":"126","author":"SH Hong","year":"2007","unstructured":"Hong SH, Cho O, Kim K, Shin HJ, Kotenko S V, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007, Jun;126(1\u20132):245\u201349. https:\/\/doi.org\/10.1016\/j.virusres.2007.03.006 PubMed PMID: 17451832.","journal-title":"Virus Res"},{"issue":"3","key":"8209_CR124","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/S00430-014-0330-9","volume":"203","author":"F Cannella","year":"2014","unstructured":"Cannella F, Scagnolari C, Selvaggi C, Stentella P, Recine N, Antonelli G, et al. Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol. 2014;203(3):177\u201384. https:\/\/doi.org\/10.1007\/S00430-014-0330-9 PubMed PMID: 24510368.","journal-title":"Med Microbiol Immunol"},{"issue":"8","key":"8209_CR125","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1128\/JVI.01773-08","volume":"83","author":"W Hou","year":"2009","unstructured":"Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, et al. Lambda interferon inhibits human Immunodeficiency virus type 1 infection of macrophages. J Virol. 2009, Apr, 15;83(8):3834\u201342. https:\/\/doi.org\/10.1128\/JVI.01773-08 PubMed PMID: 19193806.","journal-title":"J Virol"},{"issue":"1","key":"8209_CR126","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/GLIA.21076","volume":"59","author":"J Li","year":"2011","unstructured":"Li J, Hu S, Zhou L, Ye L, Wang X, Ho J, et al. Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia. 2011, Jan;59(1):58\u201367. https:\/\/doi.org\/10.1002\/GLIA.21076 PubMed PMID: 20878770.","journal-title":"Glia"},{"issue":"1\u20132","key":"8209_CR127","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/J.VIRUSRES.2011.07.011","volume":"160","author":"T Okabayashi","year":"2011","unstructured":"Okabayashi T, Kojima T, Masaki T, Yokota S-I, Imaizumi T, Tsutsumi H, et al. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 2011, Sep, 1;160(1\u20132):360\u201366. https:\/\/doi.org\/10.1016\/J.VIRUSRES.2011.07.011 PubMed PMID: 21816185.","journal-title":"Virus Res"},{"issue":"21","key":"8209_CR128","doi-asserted-by":"publisher","first-page":"11515","DOI":"10.1128\/JVI.01703-09","volume":"84","author":"NA Jewell","year":"2010","unstructured":"Jewell NA, Cline T, Mertz SE, Smirnov S V, Flano E, Schindler C, et al. Lambda interferon is the predominant interferon induced by influenza a virus infection in vivo. J Virol. 2010, Nov;84(21):11515\u201322. https:\/\/doi.org\/10.1128\/JVI.01703-09 PubMed PMID: 20739515.","journal-title":"J Virol"},{"issue":"3","key":"8209_CR129","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1398-9995.2008.01826.x","volume":"64","author":"MR Khaitov","year":"2009","unstructured":"Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, et al. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy: Eur J Allergy Clin Immunol. 2009, Mar, 1;64(3):375\u201386. https:\/\/doi.org\/10.1111\/j.1398-9995.2008.01826.x PubMed PMID: 19175599.","journal-title":"Allergy: Eur J Allergy Clin Immunol"},{"issue":"10","key":"8209_CR130","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1084\/JEM.20121401","volume":"210","author":"IF Ueki","year":"2013","unstructured":"Ueki IF, Min-Oo G, Kalinowski A, Ballon-Landa E, Lanier LL, Nadel JA, et al. Respiratory virus\u2013induced EGFR activation suppresses IRF1-dependent interferon \u03bb and antiviral defense in airway epithelium. J Exp Med. 2013, Sep, 23;210(10):1929\u201336. https:\/\/doi.org\/10.1084\/JEM.20121401 PubMed PMID: 23999497.","journal-title":"J Exp Med"},{"issue":"9","key":"8209_CR131","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1128\/JVI.79.9.5353-5362.2005","volume":"79","author":"KM Spann","year":"2005","unstructured":"Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory Syncytial virus on interferon regulatory Factor 3, NF-\u03baB, and proinflammatory cytokines. J Virol. 2005, May;79(9):5353\u201362. https:\/\/doi.org\/10.1128\/JVI.79.9.5353-5362.2005 PubMed PMID: 15827150.","journal-title":"J Virol"},{"issue":"8","key":"8209_CR132","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1128\/JVI.78.8.4363-4369.2004","volume":"78","author":"KM Spann","year":"2004","unstructured":"Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory Syncytial virus in human epithelial cells and macrophages. J Virol. 2004, Apr, 15;78(8):4363\u201369. https:\/\/doi.org\/10.1128\/JVI.78.8.4363-4369.2004 PubMed PMID: 15047850.","journal-title":"J Virol"},{"issue":"23","key":"8209_CR133","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/BLOOD-2008-11-190520","volume":"113","author":"MP Morrow","year":"2009","unstructured":"Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 2009;113(23):5868\u201377. https:\/\/doi.org\/10.1182\/BLOOD-2008-11-190520 PubMed PMID: 19304955.","journal-title":"Blood"},{"key":"8209_CR134","doi-asserted-by":"publisher","unstructured":"Egli A, Santer DM, O\u2019Shea D, Barakat K, Syedbasha M, Vollmer M, et al. IL-28B is a key Regulator of B- and T-Cell vaccine responses against influenza. PLoS Pathog. 2014, Dec, 1;10(12):e1004556. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1004556 PubMed PMID: 25503988.","DOI":"10.1371\/JOURNAL.PPAT.1004556"},{"issue":"4","key":"8209_CR135","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1189\/JLB.3A0215-041RR","volume":"98","author":"de Groen Ra","year":"2015","unstructured":"de Groen Ra, Groothuismink ZMA, Liu BS, Boonstra A, de Groen RA. IFN-\u03bb is able to augment TLR-mediated activation and subsequent function of primary human B cells. J Leukoc Biol. 2015, Oct, 1;98(4):623\u201330. https:\/\/doi.org\/10.1189\/JLB.3A0215-041RR PubMed PMID: 26130701.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"8209_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25218-x","volume":"12","author":"Q Chen","year":"2021","unstructured":"Chen Q, Coto-Llerena M, Suslov A, Teixeira RD, Fofana I, Nuciforo S, et al. Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. Nat Commun. 2021;12(1):1\u201316. https:\/\/doi.org\/10.1038\/s41467-021-25218-x PubMed PMID: 34385466.","journal-title":"Nat Commun"},{"issue":"3","key":"8209_CR137","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/HEP.29877","volume":"68","author":"N Ramamurthy","year":"2018","unstructured":"Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, et al. Impact of interferon lambda 4 genotype on interferon-stimulated gene expression during direct-acting antiviral therapy for hepatitis C. Hepatology. 2018, Sep, 1;68(3):859. https:\/\/doi.org\/10.1002\/HEP.29877 PubMed PMID: 29534310.","journal-title":"Hepatology"},{"issue":"7","key":"8209_CR138","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/JIR.2013.0113","volume":"34","author":"S Chinnaswamy","year":"2014","unstructured":"Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal Novel insights into host-virus interactions. J Interferon Cytokine Res. 2014, Jul, 1;34(7):479. https:\/\/doi.org\/10.1089\/JIR.2013.0113 PubMed PMID: 24555572.","journal-title":"J Interferon Cytokine Res"},{"issue":"28","key":"8209_CR139","doi-asserted-by":"publisher","first-page":"9245","DOI":"10.3748\/WJG.V20.I28.9245","volume":"20","author":"G Indolfi","year":"2014","unstructured":"Indolfi G, Azzari C, Resti M. Polymorphisms in the IFNL3\/IL28B gene and hepatitis C: from adults to children. World J Gastroenterol. 2014, Jul, 28;20(28):9245. https:\/\/doi.org\/10.3748\/WJG.V20.I28.9245 PubMed PMID: 25071317.","journal-title":"World J. Gastroenterol"},{"issue":"4","key":"8209_CR140","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/HEP.510280430","volume":"28","author":"DTY Lau","year":"1998","unstructured":"Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-\u03b1 therapy for chronic hepatitis C. Hepatology. 1998;28(4):1121\u201327. https:\/\/doi.org\/10.1002\/HEP.510280430 PubMed PMID: 9755252.","journal-title":"Hepatology"},{"issue":"9","key":"8209_CR141","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/J.IT.2011.07.002","volume":"32","author":"RP Donnelly","year":"2011","unstructured":"Donnelly RP, Dickensheets H, O\u2019Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011, Sep;32(9):443. https:\/\/doi.org\/10.1016\/J.IT.2011.07.002 PubMed PMID: 21820962.","journal-title":"Trends Immunol"},{"issue":"4","key":"8209_CR142","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/J.1365-2567.2008.02862.X","volume":"125","author":"S Srinivas","year":"2008","unstructured":"Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G. Interferon-\u03bb1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 2008, Dec;125(4):492. https:\/\/doi.org\/10.1111\/J.1365-2567.2008.02862.X PubMed PMID: 18547367.","journal-title":"Immunology"},{"key":"8209_CR143","unstructured":"View of serum of interferon lambda-1 level as a protein biomarker for the diagnosis of COVID-19 severity [Internet]. [https:\/\/czasopisma.umlub.pl\/curipms\/article\/view\/896\/923. 2025 Aug 13] ."},{"issue":"5","key":"8209_CR144","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","volume":"9","author":"JJ Feld","year":"2021","unstructured":"Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021, May, 1;9(5):498\u2013510. https:\/\/doi.org\/10.1016\/S2213-2600(20)30566-X PubMed PMID: 33556319.","journal-title":"LancetThe Lancet Respir Med"},{"issue":"1","key":"8209_CR145","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/S41467-021-22177-1","volume":"12","author":"P Jagannathan","year":"2021","unstructured":"Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, et al. Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021, Dec, 1;12(1):1967. https:\/\/doi.org\/10.1038\/S41467-021-22177-1 PubMed PMID: 33785743.","journal-title":"Nat Commun"},{"issue":"1","key":"8209_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-34709-4","volume":"13","author":"DM Santer","year":"2022","unstructured":"Santer DM, Li D, Ghosheh Y, Zahoor MA, Prajapati D, Hansen BE, et al. Interferon-\u03bb treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nat Commun. 2022;13(1):1\u201312. https:\/\/doi.org\/10.1038\/s41467-022-34709-4 PubMed PMID: 36385011.","journal-title":"Nat Commun"},{"issue":"5","key":"8209_CR147","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","volume":"64","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Ahn SH, Chang TT, Peng CY, Wong D, Coffin CS, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J Educ Chang Hepatol. 2016, May, 1;64(5):1011\u201319. https:\/\/doi.org\/10.1016\/j.jhep.2015.12.018 PubMed PMID: 26739688.","journal-title":"J Educ Chang Hepatol"},{"issue":"5","key":"8209_CR148","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/HAE.12947","volume":"22","author":"E Santagostino","year":"2016","unstructured":"Santagostino E, Pol S, Olveira A, Reesink HW, van Erpecum K, Bogomolov P, et al. Daclatasvir\/Peginterferon lambda-1a\/ribavirin in patients with chronic HCV infection and haemophilia who are treatment na\u00efve or prior relapsers to peginterferon alfa-2a\/ribavirin. Haemophilia. 2016, Sep, 1;22(5):692\u201399. https:\/\/doi.org\/10.1111\/HAE.12947 PubMed PMID: 27339614.","journal-title":"Haemophilia"},{"issue":"12","key":"8209_CR149","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1111\/LIV.15033","volume":"41","author":"G Sari","year":"2021","unstructured":"Sari G, Mulders CE, Zhu J, van Oord GW, Feng Z, Kreeft-Voermans JJC, et al. Treatment induced clearance of hepatitis E viruses by interferon-lambda in liver-humanized mice. Liver Int. 2021, Dec, 1;41(12):2866\u201373. https:\/\/doi.org\/10.1111\/LIV.15033 PubMed PMID: 34392598.","journal-title":"Liver Int"},{"key":"8209_CR150","doi-asserted-by":"publisher","unstructured":"Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, et al. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients. Front Immunol. 2017, May, 29;8(MAY). https:\/\/doi.org\/10.3389\/FIMMU.2017.00621.","DOI":"10.3389\/FIMMU.2017.00621"},{"issue":"6","key":"8209_CR151","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1084\/JEM.20140995","volume":"212","author":"K Blazek","year":"2015","unstructured":"Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, et al. IFN-\u03bb resolves inflammation via suppression of neutrophil infiltration and IL-1\u03b2 production. J Exp Med. 2015, Jun, 1;212(6):845. https:\/\/doi.org\/10.1084\/JEM.20140995 PubMed PMID: 25941255.","journal-title":"J Exp Med"},{"issue":"5","key":"8209_CR152","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.4049\/JIMMUNOL.2000225","volume":"205","author":"M Benhammadi","year":"2020","unstructured":"Benhammadi M, Math\u00e9 J, Dumont-Lagac\u00e9 M, Kobayashi KS, Gaboury L, Brochu S, et al. IFN-\u03bb enhances Constitutive expression of MHC class I molecules on thymic epithelial cells. J Immunol. 2020, Sep, 1;205(5):1268\u201380. https:\/\/doi.org\/10.4049\/JIMMUNOL.2000225 PubMed PMID: 32690660.","journal-title":"J Immunol"},{"issue":"2","key":"8209_CR153","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imm.13954","volume":"176","author":"B Tang","year":"2025","unstructured":"Tang B, Liu Z, Xiong H, Zhang J, Dai J. IFN-\u03bb: unleashing its potential in disease therapies from Acute inflammation regulation to cancer immunotherapy. Immunology. 2025, Oct, 1;176(2):197\u2013214. https:\/\/doi.org\/10.1111\/imm.13954 PubMed PMID: 40421666.","journal-title":"Immunology"},{"issue":"8","key":"8209_CR154","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/IMT-2015-0021","volume":"8","author":"A Lasfar","year":"2016","unstructured":"Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. IFN-\u03bb cancer immunotherapy: new kid on the block. Immunotherapy. 2016, Jul, 1;8(8):877. https:\/\/doi.org\/10.2217\/IMT-2015-0021 PubMed PMID: 27381684.","journal-title":"Immunotherapy"},{"issue":"3","key":"8209_CR155","doi-asserted-by":"publisher","first-page":"152389","DOI":"10.1016\/j.imbio.2023.152389","volume":"228","author":"TV Larsen","year":"2023","unstructured":"Larsen TV, Daugaard TF, Gad HH, Hartmann R, Nielsen AL. PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells. Immunobiology. 2023, May, 1;228(3):152389. https:\/\/doi.org\/10.1016\/j.imbio.2023.152389 PubMed PMID: 37146414.","journal-title":"Immunobiology"},{"key":"8209_CR156","doi-asserted-by":"publisher","unstructured":"Keser Y, Bumin ZS, Valiente AP, Jacobs SO, Boulant S, Stanifer ML. Basal IFN\u03bb2\/3 signaling is required for ISG expression and viral control in human intestinal epithelial cells. PLoS Pathog. 2026, Jan, 1;22(1):e1013857. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1013857 PubMed PMID: 41525418.","DOI":"10.1371\/JOURNAL.PPAT.1013857"},{"issue":"7","key":"8209_CR157","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Guerin M V, Garcia Z, Alonso R, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4+ CAR T-cell antitumor activity. Nat Cancer. 2023, Jul, 1;4(7):968\u201383. https:\/\/doi.org\/10.1038\/s43018-023-00570-7 PubMed PMID: 37248395.","journal-title":"Nat Cancer"},{"issue":"1","key":"8209_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-35948-9","volume":"14","author":"JM Mazet","year":"2023","unstructured":"Mazet JM, Mahale JN, Tong O, Watson RA, Lechuga-Vieco AV, Pirgova G, et al. IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. Nat Commun. 2023;14(1):1\u201321. https:\/\/doi.org\/10.1038\/s41467-023-35948-9 PubMed PMID: 36658158.","journal-title":"Nat Commun"},{"issue":"MAR","key":"8209_CR159","doi-asserted-by":"publisher","first-page":"248889","DOI":"10.3389\/fimmu.2017.00304","volume":"8","author":"L M\u00fcller","year":"2017","unstructured":"M\u00fcller L, Aigner P, Stoiber D. Type I interferons and natural killer cell regulation in cancer. Front Immunol. 2017, Mar, 31;8(MAR):248889. https:\/\/doi.org\/10.3389\/fimmu.2017.00304.","journal-title":"Front Immunol"},{"issue":"APR","key":"8209_CR160","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fimmu.2017.00391","volume":"8","author":"A Aquino-L\u00f3pez","year":"2017","unstructured":"Aquino-L\u00f3pez A, Senyukov V V, Vlasic Z, Kleinerman ES, Lee DA. Interferon gamma induces changes in natural killer (NK) cell ligand expression and alters NK cell-mediated lysis of pediatric cancer cell lines. Front Immunol. 2017, Apr, 6;8(APR):391. https:\/\/doi.org\/10.3389\/fimmu.2017.00391.","journal-title":"Front Immunol"},{"issue":"31","key":"8209_CR161","doi-asserted-by":"publisher","first-page":"32269","DOI":"10.1074\/JBC.M404789200","volume":"279","author":"L Dumoutier","year":"2004","unstructured":"Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko S V, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/Interferon-\u03bb1: similarities with type i interferon signaling *. J Biol Chem. 2004, Jul, 30;279(31):32269\u201374. https:\/\/doi.org\/10.1074\/JBC.M404789200 PubMed PMID: 15166220.","journal-title":"J Biol Chem"},{"key":"8209_CR162","doi-asserted-by":"publisher","unstructured":"Belanger AM, Przybylska M, Gefteas E, Furgerson M, Geller S, Kloss A, et al. Inhibiting neutral amino acid transport for the treatment of phenylketonuria. JCI Insight. 2018, Jul, 26;3(14). https:\/\/doi.org\/10.1172\/JCI.INSIGHT.121762 PubMed PMID: 30046012.","DOI":"10.1172\/JCI.INSIGHT.121762"},{"key":"8209_CR163","doi-asserted-by":"publisher","unstructured":"Wang ZZ, Wen XL, Wang N, Li XH, Guo Y, Zhu X, et al. Portraying the dark side of endogenous IFN-\u03bb for promoting cancer progression and immunoevasion in pan-cancer. J Transl Med. 2023, Dec, 1;21(1). https:\/\/doi.org\/10.1186\/S12967-023-04453-4 PubMed PMID: 37697300.","DOI":"10.1186\/S12967-023-04453-4"},{"issue":"9","key":"8209_CR164","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/JCP.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cellular Physiol. 2018, Sep, 1;233(9):6425\u201340. https:\/\/doi.org\/10.1002\/JCP.26429 PubMed PMID: 29319160.","journal-title":"J Cellular Physiol"},{"key":"8209_CR165","doi-asserted-by":"publisher","unstructured":"Liu Q, Yang C, Wang S, Shi D, Wei C, Song J, et al. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. Cell Commun Signal. 2020, Mar, 30;18(1). https:\/\/doi.org\/10.1186\/S12964-020-00557-2 PubMed PMID: 32228612.","DOI":"10.1186\/S12964-020-00557-2"},{"key":"8209_CR166","doi-asserted-by":"publisher","unstructured":"Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, et al. IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients. Arthritis Res Ther. 2013, Oct, 29;15(5). https:\/\/doi.org\/10.1186\/AR4357 PubMed PMID: 24286242.","DOI":"10.1186\/AR4357"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08209-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:01:01Z","timestamp":1782802861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08209-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8209"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08209-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declare that she has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"830"}}